Farletuzumab ecteribulin is under clinical development by Eisai and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Farletuzumab ecteribulin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Farletuzumab ecteribulin overview
Farletuzumab ecteribulin (MORAb-202) is under development for the treatment of solid tumors including advanced or metastatic endometrial cancer, non-small cell lung cancer, peritoneal cancer, epithelial ovarian cancer, fallopian tube cancer and triple-negative breast cancer. The monoclonal antibody drug conjugate consists of farletezumab antibody linked to eribulin payload. It acts by targeting tubulin and cells expressing folate receptor alpha. It is developed based on Residue-Specific Conjugation Technology (RESPECT). The drug candidate is administered via intravenous route.
Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China, and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
For a complete picture of Farletuzumab ecteribulin’s drug-specific PTSR and LoA scores, buy the report here.